Crossmark

Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial

Crossref DOI link: https://doi.org/10.1186/s13063-022-06081-7

Published Online: 2022-02-16

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kautz-Freimuth, Sibylle http://orcid.org/0000-0002-0753-8490
Redaèlli, Marcus

Isselhard, Anna

Shukri, Arim

Vodermaier, Andrea

Rhiem, Kerstin

Schmutzler, Rita

Stock, Stephanie
Funding

Funding for this research was provided by:

Landeszentrum Gesundheit Nordrhein-Westfalen (LZG TG 72 004/2016)

Universitätsklinikum Köln
License Information

Text and Data Mining valid from 2022-02-16

Version of Record valid from 2022-02-16
More Information

Article History

Received: 26 February 2021

Accepted: 3 February 2022

First Online: 16 February 2022

Change Date: 12 May 2022

Change Type: Update

Change Details: The Funding section has been updated.

Declarations

:

: Before starting this trial, this project was approved by the Ethics Committee of the Faculty of Medicine of the University of Cologne [ethical approval given 26 April 2017, reference number 17-128].

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below